} Zentaris GmbH, a 100% subsidiary of canadian Ęterna Zentaris Inc., is an integrated clinical-research driven biotechnology company with a clear focus on the treatment of benign and malignant tumors. Following its guiding principle "committed to cure" Zentaris develops innovative biopharmaceuticals for new patient-friendly therapies. With approximately 70 employees, basic research and clinical developement are integrated under the company's roof.